Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® HIV / AIDS specialty page provides HIV/AIDS-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

HIV / AIDS NEWS - Page 1

Couple-Based Intervention May Reduce Sexual Risk Behavior
Sexual risk behavior was significantly lower among men in community supervision programs who participated in couples-based intervention, in a recent study.
Experimental Antibody Infusions Shown to Suppress HIV for Up to 4 Months
In a new trial, an experimental antibody suppressed HIV in patients on short-term pause from their daily antiretroviral therapy regimens.
Can Gene Editing Tool CRISPR Dispense With HIV?
A study using monkeys provides an intriguing glimpse of the possibilities of using CRISPR gene editing technology to knock out HIV reserves in humans.
Jose Arribas, MD, on the Challenges That Come With Long-Acting Injectables
Jose Arribas, MD, discusses the challenges in the field of long-acting injectable therapy for the treatment, management, and even prevention of HIV.
 
Implants of Tenofovir Alafenamide Could Provide Protection for 6 Months, Study Says
Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.
HIV Infection in 2019: A Cure Is Not the Real News
Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reacts to news of the London patient, the second person cured of HIV infection. 
Receipt of PrEP at Study Enrollment Linked With Increased Incidence of STIs
Among gay and bisexual men, receipt of PrEP at study enrollment was linked with an increased incidence of STIs, but 25% of participants accounted for 76% of all STIs.
FDA Approves Dolutegravir/Lamivudine for Treatment-Naive Patients With HIV
Dolutegravir/lamivudine (Dovato) becomes the first 2-drug, fixed-dose complete treatment for treatment-naive patients with HIV.
FEATURED
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.